Consolidated Nerve Agent Treatment System

Anticipated Release Date: Q1FY25

FDA approval of a multi-drug autoinjector to reduce logistical burden on the warfighter and increase survivability

Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity. 

Complete the form below and a program representative will reach out to you shortly to support you through the process. 

Contact MCDC: Consolidated Nerve Agent Treatment System